• What Does the Private Sector Really Think About Priority Review Vouchers?

    We have been very interested in the healthy debate about the impact of the FDA's Priority Review Voucher Program and its effectiveness in actually stimulating private sector investment in new neglected disease product development. BVGH recently surveyed companies with active drug or vaccine programs in one of the 16 PRV-eligible neglected tropical diseases to hear their thoughts on the value of this program. Our results were published last week in PLoS Neglected Tropical Diseases.

  

Catalyzing research for neglected tropical diseases

02/20/2013
In this article, WIPO Magazine hears from WIPO Re:Search partners about why the initiative is creati...

Open innovation

10/04/2012
European Biopharmaceutical Review features the WIPO Re:Search program in its Autumn 2012 issue. Read...

Drug repurposing

10/02/2012
Chemical & Engineering News reports on the recent trend to find new uses for approved drugs and shel...